Author of

• 25971

  +

  P3.17 - Treatment of Locoregional Disease - NSCLC (Not CME Accredited Session) (ID 983)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall

  • 27799

    +

    P3.17-07 - The Beneficial Effect of the High Dose Irradiation During Concurrent Chemoradiotherapy in Locoregional Advanced Non-Small Cell Lung Cancer (ID 13115)

    12:00 - 13:30  |  Author(s): Myungsoo Kim
    • Abstract

    Background
    

    Purpose: To investigate the effectiveness of high dose irradiation in locoregional advanced non-small cell lung cancer (NSCLC) after concurrent chemoradiotherapy (CCRT).

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    Methods: We retrospectively analyzed 36 patients with stage III NSCLC treated with CCRT between January 2011 and March 2016. CCRT was consisted of weekly chemotherapy using paclitaxel/cisplatin, docetaxel/cisplatin, etoposide/cisplatin or cisplatin alone and median dose of 66 Gy (range 50.0 ~ 73.5 Gy) involved field irradiation during 7-8 weeks. The primary and secondary endpoints were overall survival (OS) and locoregional progression free survival (LRPFS), respectively. The OS and LRPFS were calculated from the start of CCRT using the Kaplan-Meier method. Univariate analysis was done using log-rank test. Significant variables on univariate analysis were included into multivariate analysis using Cox proportional harzard model. Toxicities were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

    4c3880bb027f159e801041b1021e88e8 Result
    

    Results: The median follow up duration was 8 months (range 1 ~ 64 month). Among 36 patients, 22 (61.1%) patients showed partial response, 8 (22.2%) patients had stable disease. The 1- and 2-year OS rates were 54.0% and 46.8%. The median OS was 4.2 months in the low dose group (< 64.8 Gy) and 35.4 months in the high dose group (≥ 64.8 Gy) (p < 0.001). The median LRPFS was 4 months in the low dose group and 16.1 months in the high dose group (p < 0.001). The high dose group was shown a significantly better OS and LRPFS. Radiation dose was significantly associated with OS (HR 0.18, p=0.001) and LRPFS (HR 0.24, p=0.013) on multivariate analysis. Grade ≥3 pneumonitis, esophagitis, and hematologic toxicity were shown in 5.6%, 8.3%, and 22.2% of patients.

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    Conclusions: High dose irradiation may improve treatment outcomes for patients with locoregional advanced NSCLC after CCRT. However, further investigation should be required to confirm our results.

    6f8b794f3246b0c1e1780bb4d4d5dc53